<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="368">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02126748</url>
  </required_header>
  <id_info>
    <org_study_id>FVG003</org_study_id>
    <nct_id>NCT02126748</nct_id>
  </id_info>
  <brief_title>The Effectiveness of AAD and IPV to Treat Hospitalized Infants (&lt;2years) With Acute Viral Bronchiolitis.</brief_title>
  <official_title>The Effectiveness of Assisted Autogenic Drainage (AAD) and Intrapulmonary Percussive Ventilation (IPV) to Treat Hospitalized Infants (&lt;2years) With Acute Viral Bronchiolitis: a Randomised Clinical Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vrije Universiteit Brussel</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vrije Universiteit Brussel</source>
  <oversight_info>
    <authority>Belgium: Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the effectiveness of two airway clearance
      techniques; Intrapulmonary Percussive Ventilation and Assisted Autogenic Drainage in
      hospitalized infants under the age of 2 with acute viral bronchiolitis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Actual">January 2015</completion_date>
  <primary_completion_date type="Actual">January 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Length of Hospital Stay</measure>
    <time_frame>6 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Previously publised data ( Luo et al. 2011) showed that the average hospital stay for infants with acute viral bronchiolitis, inhaling 4 ml NaCl3%, three times /day is 6 days ( SD 1,2)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Wang Score</measure>
    <time_frame>before treatment, immediately after treatment and 1h after treatment</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heartrate</measure>
    <time_frame>before, after and 1h after intervention</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxygen Saturation (SaO2)</measure>
    <time_frame>before, after and 1h after treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>oxygen saturation (SaO2) measured by pulse -oximetry</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">103</enrollment>
  <condition>Bronchiolitis</condition>
  <arm_group>
    <arm_group_label>Intrapulmonary Percussive Ventilation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 min of IPV administered to the patient inhalation 4ml hypertonic saline 3% 3x/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Assisted Autogenic Drainage</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>20 min of AAD administered to the patient inhalation 4ml hypertonic saline 3% 3x/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>20 min of bouncing administered tot the patient inhalation 4ml hypertonic saline 3% 3x/day</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>inhalation 4ml hypertonic saline 3% 3x/day</intervention_name>
    <arm_group_label>Intrapulmonary Percussive Ventilation</arm_group_label>
    <arm_group_label>Assisted Autogenic Drainage</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Intrapulmonary Percussive Ventilation</intervention_name>
    <arm_group_label>Intrapulmonary Percussive Ventilation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Assisted Autogenic Drainage</intervention_name>
    <arm_group_label>Assisted Autogenic Drainage</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  first period of wheezing

          -  Wang score between 3 and 7

          -  age &lt; 24 months

          -  Sa02&gt; 90%

        Exclusion Criteria:

          -  ICU patients

          -  mechanical ventilation

          -  use of antibiotics

          -  use of corticosteroids

          -  gestational age &lt; 34 weeks

          -  chronic cardiac or pulmonary disease

          -  no parental consent
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>24 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Uz Brussel</name>
      <address>
        <city>Jette</city>
        <state>Brussels</state>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <lastchanged_date>March 10, 2015</lastchanged_date>
  <firstreceived_date>April 24, 2014</firstreceived_date>
  <firstreceived_results_date>February 23, 2015</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vrije Universiteit Brussel</investigator_affiliation>
    <investigator_full_name>Filip Van Ginderdeuren</investigator_full_name>
    <investigator_title>PT,Drs</investigator_title>
  </responsible_party>
  <keyword>bronchiolitis</keyword>
  <keyword>Wang score</keyword>
  <keyword>Sa02</keyword>
  <keyword>airway clearance techniques</keyword>
  <keyword>intrapulmonary percussive ventilation</keyword>
  <keyword>assisted autogenic drainage</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Bronchiolitis</mesh_term>
    <mesh_term>Bronchiolitis, Viral</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Intrapulmonary Percussive Ventilation</title>
          <description>20 min of IPV administered to the patient inhalation 4ml hypertonic saline 3% 3x/day
inhalation 4ml hypertonic saline 3% 3x/day
Intrapulmonary Percussive Ventilation</description>
        </group>
        <group group_id="P2">
          <title>Assisted Autogenic Drainage</title>
          <description>20 min of AAD administered to the patient inhalation 4ml hypertonic saline 3% 3x/day
inhalation 4ml hypertonic saline 3% 3x/day
Assisted Autogenic Drainage</description>
        </group>
        <group group_id="P3">
          <title>Control</title>
          <description>20 min of bouncing administered to the patient inhalation 4ml hypertonic saline 3% 3x/day</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="34"/>
                <participants group_id="P3" count="36"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="31"/>
                <participants group_id="P3" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Intrapulmonary Percussive Ventilation</title>
          <description>20 min of IPV administered to the patient inhalation 4ml hypertonic saline 3% 3x/day</description>
        </group>
        <group group_id="B2">
          <title>Assisted Autogenic Drainage</title>
          <description>20 min of AAD administered to the patient inhalation 4ml hypertonic saline 3% 3x/day</description>
        </group>
        <group group_id="B3">
          <title>Control</title>
          <description>20 min of bouncing administered tot the patient inhalation 4ml hypertonic saline 3% 3x/day</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="31"/>
                <measurement group_id="B2" value="31"/>
                <measurement group_id="B3" value="31"/>
                <measurement group_id="B4" value="93"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="31"/>
                <measurement group_id="B2" value="31"/>
                <measurement group_id="B3" value="31"/>
                <measurement group_id="B4" value="93"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
                <measurement group_id="B4" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
                <measurement group_id="B4" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="15"/>
                <measurement group_id="B2" value="16"/>
                <measurement group_id="B3" value="18"/>
                <measurement group_id="B4" value="49"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="16"/>
                <measurement group_id="B2" value="15"/>
                <measurement group_id="B3" value="13"/>
                <measurement group_id="B4" value="44"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Belgium</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="31"/>
                <measurement group_id="B2" value="31"/>
                <measurement group_id="B3" value="31"/>
                <measurement group_id="B4" value="93"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Length of Hospital Stay</title>
        <description>Previously publised data ( Luo et al. 2011) showed that the average hospital stay for infants with acute viral bronchiolitis, inhaling 4 ml NaCl3%, three times /day is 6 days ( SD 1,2)</description>
        <time_frame>6 days</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Intrapulmonary Percussive Ventilation</title>
            <description>20 min of IPV administered to the patient inhalation 4ml hypertonic saline 3% 3x/day
inhalation 4ml hypertonic saline 3% 3x/day
Intrapulmonary Percussive Ventilation</description>
          </group>
          <group group_id="O2">
            <title>Assisted Autogenic Drainage</title>
            <description>20 min of AAD administered to the patient inhalation 4ml hypertonic saline 3% 3x/day
inhalation 4ml hypertonic saline 3% 3x/day
Assisted Autogenic Drainage</description>
          </group>
          <group group_id="O3">
            <title>Control</title>
            <description>20 min of bouncing administered to the patient inhalation 4ml hypertonic saline 3% 3x/day</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="31"/>
                  <measurement group_id="O2" value="31"/>
                  <measurement group_id="O3" value="31"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Length of Hospital Stay</title>
            <description>Previously publised data ( Luo et al. 2011) showed that the average hospital stay for infants with acute viral bronchiolitis, inhaling 4 ml NaCl3%, three times /day is 6 days ( SD 1,2)</description>
            <units>days</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="3.5" spread="1.3"/>
                  <measurement group_id="O2" value="3.6" spread="1.4"/>
                  <measurement group_id="O3" value="4.5" spread="1.9"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Wang Score</title>
        <time_frame>before treatment, immediately after treatment and 1h after treatment</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Heartrate</title>
        <time_frame>before, after and 1h after intervention</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Oxygen Saturation (SaO2)</title>
        <description>oxygen saturation (SaO2) measured by pulse -oximetry</description>
        <time_frame>before, after and 1h after treatment</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Intrapulmonary Percussive Ventilation</title>
          <description>20 min of IPV administered to the patient inhalation 4ml hypertonic saline 3% 3x/day
inhalation 4ml hypertonic saline 3% 3x/day
Intrapulmonary Percussive Ventilation</description>
        </group>
        <group group_id="E2">
          <title>Assisted Autogenic Drainage</title>
          <description>20 min of AAD administered to the patient inhalation 4ml hypertonic saline 3% 3x/day
inhalation 4ml hypertonic saline 3% 3x/day
Assisted Autogenic Drainage</description>
        </group>
        <group group_id="E3">
          <title>Control</title>
          <description>20 min of bouncing administered tot the patient inhalation 4ml hypertonic saline 3% 3x/day</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Filip Van Ginderdeuren</name_or_title>
      <organization>Vrije Universiteit Brussel</organization>
      <phone>+3224763916</phone>
      <email>filip.vanginderdeuren@uzbrussel.be</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
